Apple lawsuit against OpenAI has reached its first major procedural challenge, with the ChatGPT developer asking a US federal judge to dismiss allegations that it acquired or used trade secrets taken by former Apple employees.

OpenAI submitted its 31-page dismissal motion on Wednesday in the US District Court for the Northern District of California. The filing argues that Apple has not adequately identified protectable trade secrets or alleged facts showing that OpenAI misappropriated confidential information.

Apple filed the case on July 10 against OpenAI, its io Products hardware operation, former Apple Vice President Tang Yew Tan, and former electrical engineer Chang Liu. The complaint accuses the defendants of obtaining information connected to Apple’s product development, manufacturing, components, testing, and supply chain operations.

The allegations have not been proven, and OpenAI denies possessing or seeking Apple’s trade secrets. US District Judge Edward Davila must now decide whether Apple’s complaint contains enough factual detail for the litigation to continue.

OpenAI Challenges the Apple Lawsuit

OpenAI’s motion focuses initially on how Apple described the information it claims was stolen. According to OpenAI, the complaint relies on generalized product-development categories without identifying the protected information with enough precision.

Trade secret plaintiffs face a difficult balance at the beginning of litigation. Apple must describe the protected material sufficiently to establish a plausible legal claim, but revealing the material publicly could expose the same information it is trying to protect.

Sensitive details can later be handled under seal or through a protective order. At the dismissal stage, however, Apple must still provide enough information for the court to distinguish genuine trade secrets from general engineering knowledge, employee experience, or skills acquired through years of work.

OpenAI argues that Apple has not crossed that threshold. Its motion says the complaint fails to establish ownership of a protectable trade secret and does not plausibly allege that OpenAI acquired, disclosed, or used such information.

The filing also disputes the commercial premise behind Apple’s accusations. OpenAI says it is developing products that are different from Apple’s hardware and has no need or desire to use the iPhone maker’s confidential material.

That position does not settle whether information was taken. A company can potentially misappropriate trade secrets even when its eventual product has a different design. The court’s immediate task is narrower: determining whether Apple has alleged facts that could support its claims if those facts are later proven.

Disputed Access to Apple Information

Apple’s complaint centers partly on Chang Liu, who spent eight years working as a senior system electrical engineer at the company before joining OpenAI in January 2026.

Apple alleges that Liu retained an Apple-issued computer and accessed confidential technical information after leaving. It claims he exploited residual authentication access on multiple occasions to obtain internal documents while already working for OpenAI.

OpenAI presents a different explanation. It says Apple employees contacted Liu after his departure and asked him to help locate files needed for ongoing Apple work. The company published redacted messages that it says support this account.

OpenAI argues that Apple’s systems and policies allowed personal and corporate information to become intermingled through iCloud accounts. Former employees, it says, could retain access to Apple files without requesting it or realizing that access remained active.

The motion maintains that Apple cannot treat the foreseeable effects of its own access-management practices as proof that former employees intentionally stole data. Apple, in contrast, alleges that its records document repeated access to restricted information rather than an accidental discovery of lingering permissions.

These competing accounts are likely to become central if the case enters discovery. Authentication logs, downloaded files, device records, internal communications, and employment timelines could establish whether access was deliberate, what information was obtained, and whether it reached anyone working on OpenAI products.

A dismissal motion normally tests whether the complaint states a legally sufficient claim. It is not a trial, and the judge is not expected to resolve every factual disagreement using competing evidence at this point.

Tang Tan and OpenAI’s Hardware Team

Apple separately accuses Tang Tan, OpenAI’s chief hardware officer, of seeking confidential information from Apple employees during recruiting conversations.

Tan spent more than 24 years at Apple and worked on products including the iPhone, Apple Watch, AirPods, and iPod. He later helped establish io Products with former Apple design chief Jony Ive and other collaborators. OpenAI acquired the hardware company as part of its effort to create a family of devices built around artificial intelligence.

Apple alleges that Tan used confidential project names, retained internal materials, and encouraged job candidates to discuss unreleased components or bring physical parts to interviews. OpenAI rejects the claim that these interactions formed a coordinated effort to collect Apple secrets.

OpenAI says Tan repeatedly instructed employees that confidential information from previous employers could not be brought into its organization. It also offers an alternative explanation for an Apple offboarding document found in his possession, arguing that Tan retained it to help incoming employees comply with Apple’s departure procedures.

Apple’s position is that the document and recruiting communications must be examined alongside the other alleged conduct. It describes the events as part of a connected campaign rather than isolated employment or administrative issues.

The dispute comes during intense competition for engineers capable of developing consumer AI hardware. Apple alleges that more than 400 former employees have moved to OpenAI, although hiring people from a competitor does not by itself establish trade secret misappropriation.

A company must generally connect recruitment to the acquisition, disclosure, or use of protected information. OpenAI is relying heavily on that distinction, presenting Apple’s lawsuit as an attempt to respond to employee departures and its difficulties competing for AI talent.

Apple Seeks Immediate Restrictions

OpenAI’s dismissal request arrives shortly after Apple asked the court for a preliminary injunction. Apple wants restrictions imposed while the lawsuit proceeds, arguing that it could suffer harm if its confidential information is used during OpenAI’s hardware development.

The requested relief would prevent OpenAI and the individual defendants from acquiring, accessing, using, or disclosing the alleged trade secrets. Apple has also requested expedited discovery and forensic examination of relevant devices and accounts.

OpenAI says those restrictions are unnecessary because it does not possess or want Apple’s protected information. It has described Apple’s request as based on false information and has offered to cooperate in addressing specific concerns.

The two companies also disagree over their communications before the lawsuit. Apple initially said its concerns had been raised with OpenAI months earlier. OpenAI responded that Apple’s outside lawyers contacted the wrong person after confusing names and incorrectly described a conversation with OpenAI’s general counsel.

OpenAI says Apple did not present the specific accusations before filing the case and that the companies had previously discussed resolving any access issues. Apple has since provided additional information in support of its injunction request, including allegations involving other former employees.

These disputes have moved beyond ordinary court filings. OpenAI published messages and emails on its website to support its version of events, calling Apple’s lawsuit aggressive and poorly investigated. Apple has primarily presented its account through formal legal submissions.

Judge Davila could dismiss some or all of Apple’s claims, deny the motion, or allow Apple to amend its complaint with more specific allegations. Even a dismissal would not necessarily end the case if permission to revise the complaint is granted.

The next scheduled public test is an October 1 hearing covering Apple’s preliminary injunction and request for early discovery. That proceeding may determine whether OpenAI faces immediate limits on its hardware work before the underlying trade secret claims receive a full evidentiary review.

The post Apple Lawsuit: OpenAI Seeks Dismissal of Trade Secrets Case appeared first on AppleMagazine.

For decades, the scientific community has recognized the gut microbiome—the intricate ecosystem of bacteria and microorganisms residing within the human intestine—as a potential key player in colorectal cancer development. Yet, the complexity and variability of microbiome data have often obscured clear, reproducible links. Now, an ambitious new study spearheaded by the Mi-EOCRC consortium, which includes pioneering teams at EMBL Heidelberg, has transcended these obstacles by analyzing an unprecedented breadth of data to unearth a universal microbiome signature associated with colorectal cancer.

Garnering insights from an extensive meta-analysis of 27 studies with over 6,700 gut microbiome profiles, the researchers uncovered microbial patterns that remain consistent across diverse populations, sequencing methodologies, and age groups—illuminating a microbial footprint intrinsic to colorectal cancer itself. Their integrative approach not only encompassed stool samples but also expanded to 906 intestinal tissue specimens, revealing striking similarities between microbes colonizing tumors and those present in fecal matter.

This landmark research fundamentally shifted microbiome science by developing innovative computational tools capable of harmonizing heterogeneous datasets produced by different sequencing technologies. Such methodological rigor was critical in overcoming previous barriers of reproducibility that have long plagued microbiome studies. Central to their approach was a bespoke machine learning algorithm adept at categorizing microbiomes along a continuum from ‘healthy’ to ‘cancer-like,’ yielding a quantifiable score that can be leveraged across disparate human gut microbiome datasets, including those derived from dietary interventions.

This algorithmic precision allowed the consortium to isolate a colorectal cancer-associated microbiome signature that transcends traditional cohort boundaries. Intriguingly, the signature appears robust not only in late-stage disease but also in early-onset cases, dispelling prior uncertainty surrounding the microbiome’s role throughout the disease timeline. The discovery underscores the microbiome’s potential as an informative biomarker capable of reflecting the intricate disease ecology.

Moreover, by comparing tumor tissue microbial profiles with those detected in stool, the study illuminated how colorectal cancer’s microbial hallmarks are mirrored across sample types. Although the microbial signature was more readily detectable in advanced tumors or those proximal to the rectum, early-stage lesions exhibited a detectable microbial presence as well. This finding deepens our understanding of tumor-microbiome crosstalk and raises critical questions regarding how microbial communities might influence tumor progression via metabolic and signaling pathways.

Despite these advances, the researchers caution that pre-cancerous adenomas—often the target of preventive strategies—remain notoriously elusive in stool-derived microbiome analyses. The microbial alterations associated with adenomas were subtler and less consistent than those observed in full-fledged cancers. Sophisticated machine learning models specifically aimed at adenoma detection showed variable success across cohorts, highlighting the need for methodological refinement before such tools can make meaningful clinical contributions.

Diet emerged as another pivotal factor shaping cancer-associated microbial patterns. A compelling link was established between low dietary fiber intake and a heightened presence of the colorectal cancer microbiome signature. Conversely, dietary interventions increasing fiber consumption correlated with marked reductions in this cancer-associated microbial pattern. These findings reinforce the concept that diet—and particularly fiber—modulates the gut environment in ways that could impact cancer risk and progression, opening avenues for microbiome-focused preventive strategies rooted in nutrition.

Delving further into microbial taxonomy, the study provided high-resolution insights into Fusobacterium species, bacteria recurrently implicated in colorectal cancer. The researchers delineated notable differences among subspecies, with Fusobacterium nucleatum subsp. animalis exhibiting consistent cancer enrichment worldwide, whereas others showed distinct geographic distributions, predominantly in Asian populations. This nuanced understanding challenges the oversimplification of grouping all Fusobacteria uniformly and underscores the importance of subspecies-level resolution for future microbiome research and therapeutic targeting.

Open science was a cornerstone of this monumental undertaking. By consolidating thousands of publicly available microbiome profiles, the researchers achieved a scale of analysis previously unattainable, setting a new standard for evidence synthesis in microbiome studies. This collective data sharing facilitates reproducible science and paves the way for scalable, global approaches to understanding the microbiome’s role in human disease.

While the study stops short of proposing an immediate diagnostic application, it lays critical groundwork for the development of microbiome-informed clinical tools. Compared to existing non-invasive colorectal cancer screening tests like the fecal immunochemical test, microbiome-based classifiers are not yet on par for sensitivity or specificity. However, the reproducible microbial signature defined here could serve as a foundational reference for future machine-learning models, enabling improved risk stratification and early detection when integrated with other clinical markers.

The implications of this research ripple beyond colorectal cancer alone. The computational tools and conceptual frameworks unveiled may be applied to myriad disease contexts where the microbiome plays a role. Furthermore, the iterative feedback loop between dietary modulation and microbial signatures encourages a personalized medicine approach that incorporates lifestyle factors into disease management.

Finally, this research highlights the intricate dance between host, microbes, and environment that shapes disease landscapes. As microbiome science marches forward, studies like this exemplify the power of interdisciplinary collaboration, computational innovation, and open data stewardship to unravel complex biomedical puzzles, bringing us closer to novel interventions and preventive strategies that could transform patient outcomes worldwide.

Subject of Research: People
Article Title: Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across onset age and sequencing method
News Publication Date: 24-Jun-2026
Web References: http://dx.doi.org/10.1016/j.chom.2026.05.030
Image Credits: Daniela Velasco/EMBL
Keywords: Colorectal cancer, Human microbiota, Gut microbiota

In a groundbreaking advancement that could reshape the landscape of molecular biology, researchers have unveiled a high-resolution method for single-cell sequencing of trans-spliced mRNA, setting new benchmarks in cellular transcriptomics. This state-of-the-art technique, detailed in a recent publication by Cosentino and colleagues, promises unprecedented insight into the complex mechanisms governing RNA splicing and gene expression at a single-cell level, a domain critical for understanding diverse biological processes and disease states.

Traditional RNA sequencing methods often struggle to capture the nuances of trans-splicing—an RNA processing event where exons from different pre-mRNA molecules are joined together. This unique form of splicing has been relatively underexplored, largely due to technical limitations in distinguishing trans-spliced variants from the more common cis-spliced transcripts. The innovation presented in this protocol addresses these challenges head-on by incorporating enhanced molecular tagging and amplification strategies to faithfully preserve the native architecture of trans-spliced mRNAs.

The power of single-cell sequencing lies in its ability to discern cellular heterogeneity that bulk sequencing methods average out. By applying this resolution to trans-splicing events, the new protocol enables researchers to map how individual cells harness this process to diversify their transcriptomes. This can reveal regulatory layers previously masked in population-level analyses, providing clues about cell type-specific functions, developmental trajectories, and responses to environmental stimuli.

Central to the protocol’s success is its meticulous capture of the transcript’s 5’ and 3’ ends, allowing unambiguous identification of trans-spliced junctions. The approach leverages novel enzymatic reactions and ligation steps carefully optimized to maintain sequence integrity, enabling high-fidelity reconstruction of splicing landscapes. Moreover, the method integrates seamlessly with established single-cell RNA sequencing platforms, widening accessibility and potential for widespread adoption.

The practical implications of this development are vast. Researchers can now probe the role of trans-splicing in normal physiology and pathogenesis with precision. Given that aberrant RNA splicing is implicated in various cancers and genetic disorders, understanding trans-splicing patterns at the single-cell level could illuminate new biomarkers and therapeutic targets. Furthermore, tissues with complex cell compositions, such as the brain or immune system, stand to benefit profoundly from this refined analytical lens.

Implementing this protocol requires meticulous experimental execution. Steps include cell isolation, mRNA extraction under conditions preserving RNA integrity, strategic reverse transcription with specialized primers, as well as a series of purification and amplification cycles designed to enrich for trans-spliced sequences. Each phase has been rigorously characterized to maximize sensitivity and specificity, ensuring reproducible outcomes across diverse sample types.

Bioinformatic analysis pipelines accompanying the protocol are equally sophisticated. They employ advanced algorithms capable of distinguishing genuine trans-splicing events from experimental artifacts or sequencing errors. These computational tools facilitate high-confidence annotation of transcripts, visualization of splicing diversity, and quantification of junction abundance at single-cell resolution, pushing the analytical frontier forward.

Beyond capturing static snapshots, the technology opens pathways to dynamic studies. Scientists can track how trans-splicing activity varies during cellular differentiation, in response to external cues, or throughout disease progression. This temporal dimension adds a vital layer of understanding to RNA biology’s functional repertoire, potentially revealing regulatory checkpoints amenable to therapeutic modulation.

The introduction of this high-resolution sequencing method also underscores the increasing convergence of experimental and computational biology. It reflects a growing recognition that unraveling complex molecular phenomena demands integrated approaches combining cutting-edge laboratory techniques with robust data science. This synergy not only accelerates discovery but democratizes access to intricate biological insights.

Intriguingly, this approach may shed light on evolutionary aspects of splicing. Differences in trans-splicing prevalence and patterns across species and cell types could inform hypotheses about RNA processing’s adaptive significance. Delineating these evolutionary narratives may provide broader context for interpreting functional data and guiding synthetic biology applications.

Moreover, the methodology’s adaptability hints at future expansions. For example, coupling this protocol with spatial transcriptomics could map trans-spliced mRNAs within tissue architecture, or integrating with proteomics could link transcript variants to protein isoform expression. Such multidimensional analyses hold promise for unraveling the intricate web connecting genotype to phenotype.

As research workflows adopt this technology, anticipated challenges include managing increased data complexity and scaling up throughput for large single-cell atlases. Nonetheless, the benefits—unveiling the hidden layers of transcriptomic regulation with unprecedented clarity—far outweigh these hurdles. The authors’ thorough validation in diverse biological contexts allays concerns about adaptability and robustness.

Ultimately, this state-of-the-art protocol propels trans-splicing research to new heights, furnishing the scientific community with a versatile toolset to decode RNA’s role in health and disease at unparalleled resolution. It exemplifies a milestone where technological ingenuity meets biological inquiry, heralding a new era in transcriptomic sciences.

As this methodology gains traction, it is poised to catalyze transformative discoveries, deepen our molecular understanding, and inspire follow-up innovations. The potential ripple effects extend from basic science to clinical diagnostics, underlining the enduring impact of pioneering single-cell approaches in unlocking cellular complexity comprehensively.

---

Subject of Research: High-resolution single-cell sequencing of trans-spliced mRNA

Article Title: High-resolution single-cell sequencing of trans-spliced mRNA

Article References:
Cosentino, R.O., Keneskhanova, Z., Esser, S. et al. High-resolution single-cell sequencing of trans-spliced mRNA. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01373-7

DOI: https://doi.org/10.1038/s41596-026-01373-7

Image Credits: AI Generated

After nearly a quarter of a century operating as a private company, with its financial accounts a closely guarded secret, SpaceX on Wednesday afternoon released a detailed accounting of its business in a nearly 400-page S-1 filing with the US Securities and Exchange Commission.

SpaceX, founded in 2002 and still led by Elon Musk, submitted the filing in anticipation of an initial public offering of its stock as soon as June 12.

The document revealed no major surprises about the company's space operations, but there was a trove of details about its sprawling operations, which now encompass launch, spaceflight, space-based Internet, and, thanks to its recent acquisition of Musk's xAI, social media and AI.

Read full article

Comments

© SpaceX